Final analysis of the Keynote-826 phase III trial, has shown that adding pembrolizumab to chemotherapy has increased progression-free survival (PFS) and overall survival (OS) in patients with persistent, recurrent, or metastatic cervical cancer. Following randomization of 617 patients, those who received bevacizumab indicated "grade >3 treatment-related adverse events occurred in 74% of patients in the pembrolizumab arm and 66.8% in the placebo arm."
To learn more about the Keynote-826 trial, click here.
Source mentioned:
Lorusso D, Colombo N, Dubot C, et al. Pembrolizumab Plus Chemotherapy for Advanced and Recurrent Cervical Cancer: Final Analysis According to Bevacizumab Use in the Randomized KEYNOTE-826 Study. Annals of Oncology; Published online 9 October 2024. DOI: https://doi.org/10.1016/j.annonc.2024.10.002
Improved progression-free and overall survival with pembrolizumab plus chemotherapy regardless of bevacizumab use simplifies a difficult decision in advanced cervical cancer. When benefit holds with or without an additional agent, clinicians can weigh toxicity and access more honestly instead of assuming more is always better. Updates like this are regularly covered on onc brothers, where the focus stays on what actually extends life for patients in everyday practice.
ReplyDelete